Toll Free: 1-888-928-9744

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Peripheral neuropathy is the nerve damaged that is caused by diabetes and constant high blood sugar. This results in to loss of sensation, numbness, and pain in your hands, fetes and legs.  The disease is considered to be the most common complication of diabetes.  In addition, more or less 60% to 70% of all people will ultimately develop peripheral neuropathy but not all go through pain.

The overall cost of curing foot ulcers and DPN are projected assuming that occurrence rates remain the same throughout a year.  In addition, Regular prevalence does not need at the same patients stay in that health state.

Diabetic peripheral neuropathy (DPN) develops slowly and worsens over time as the condition does not emerge overnight. Also, they people suffering have condition long before they are diagnosed with diabetes.   Patient suffering with diabetes for many years may augment the tendency of getting diagnosed with diabetic neuropathy. Although, there are few methods and research designs for diabetic peripheral neuropathy are recognized in the worldwide market.

One of the key methods implemented in the U.S is a cost-of-illness model which was used to calculate several numbers of diabetic individuals who are suffering from diabetic peripheral neuropathy in the region. Incidence rates and prevalence were estimated from published studies and applied to the general U.S Population.  Although, total cost was valued in 2001 U.S dollars. This is likely to impact the overall diabetic peripheral neuropathy market. 

According to the report, major market players are working on new techniques, methods and approaches to demonstrate new treatment techniques, Key regions operating in the diabetic peripheral neuropathy market are Asia Pacific, Europe and the U.S .Around 3.2% of the people in the US are suffering from diabetes and are estimated that over 50% have some degree of peripheral neuropath. In the region, the total annual cost of curing   DPN and its complications was around $10 billion. 

The overall cost of curing foot ulcers and DPN are projected assuming that occurrence rates remain the same throughout a year.  In addition, Regular prevalence does not need at the same patients stay in that health state
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Diabetic Peripheral Neuropathy Overview 6
Therapeutics Development 7
Pipeline Products for Diabetic Peripheral Neuropathy - Overview 7
Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis 8
Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies 9
Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 10
Diabetic Peripheral Neuropathy - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Diabetic Peripheral Neuropathy - Products under Development by Companies 13
Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes 14
Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 15
Astellas Pharma Inc. 15
BioChemics, Inc. 16
Cebix Incorporated 17
Pfizer Inc. 18
ViroMed Co., Ltd. 19
Diabetic Peripheral Neuropathy - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Antimunocel - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ASP-8477 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
benfotiamine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CBX-129801 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CNV-2197944 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
epalrestat - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PF-05089771 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VM-202 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Diabetic Peripheral Neuropathy - Recent Pipeline Updates 43
Diabetic Peripheral Neuropathy - Dormant Projects 46
Diabetic Peripheral Neuropathy - Discontinued Products 47
Diabetic Peripheral Neuropathy - Product Development Milestones 48
Featured News & Press Releases 48
Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50
List of Tables
Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2015 7
Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Diabetic Peripheral Neuropathy - Pipeline by Astellas Pharma Inc., H1 2015 15
Diabetic Peripheral Neuropathy - Pipeline by BioChemics, Inc., H1 2015 16
Diabetic Peripheral Neuropathy - Pipeline by Cebix Incorporated, H1 2015 17
Diabetic Peripheral Neuropathy - Pipeline by Pfizer Inc., H1 2015 18
Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co., Ltd., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Diabetic Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H1 2015 43
Diabetic Peripheral Neuropathy - Dormant Projects, H1 2015 46
Diabetic Peripheral Neuropathy - Discontinued Products, H1 2015 47 



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify